Pharma BD Deal Intelligence
Pfizer licensed SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, from 3SBio, paying $1.25B upfront plus a $100M equity investment in a deal worth up to $6.05B (including up to $4.8B in milestones) for global rights ex-China in lung, colorectal and gynecologic cancers. The deal closed July 24, 2025. As of ASCO 2026, Pfizer is advancing the asset in pivotal development -- the Phase 3 Symbiotic-Lung-01 study in first-line NSCLC (plus chemotherapy, regardless of PD-L1 status) and the Phase 3 Symbiotic-GI-03 study in first-line metastatic colorectal cancer -- alongside updated Phase 2 first-line NSCLC monotherapy data.